This is the old version of SRDR. The next, SRDRplus is available! Registration of your SRDRPlus account is free and approval is automatic. Click Here to register an SRDRPlus account.

Advanced Search

Extraction Form Preview:

Comparative Studies


Arm Name Suggestions

Arm Title Arm Description User Note
ALA
All n-3 PUFAs (ALA+DHA+EPA)
DHA
"Fish oil" (DHA+EPA)
DHA
EPA
Placebo
Low n-3 diet
No intervention
Placeholder
Fish
Fish + Fish oil

Arm Details

Question 1
Question 2
Row Headers
Dose (g/day)
ALA
EPA
DHA
EPA+DHA ("fish oil")
DPA
SDA
Total Omega-3
Other (specify)
Total oil (n-3 & other)
Question 3





... Specify

Question 4
...What reported
...What reported

Question 5
Row Headers
Dropouts
Denominator
Percent
Reasons
Arm
Question 6

Design Details and Enrollment

Question 1
Question 2





...Describe:
Question 3





Question 4
...Specify


Question 5
Question 6
Question 7












... Specify

Question 8
Question 9
Question 10
Question 11



Question 12

... Define:
... Define:
... Define:
... Define:
... Define:
... Define:
... Define:
... Define:
... Define:
Question 13
...Which subgroups?

Question 14
...Which predictors/variables?

Question 15


Question 16

Baseline Characteristics Fields

Question 1
Question 2
Row Headers
%
Describe
White/European
Black/African-American/etc.
Asian
Hispanic
Inuit/Eskimo
Question 3
Row Headers
Mean (or "ND")
Unit
Median
SD
SE
Range (min,max)
Age
Systolic Blood Pressure (SBP)
Diastolic Blood Pressure
Mean Arterial Pressure (MAP)
Total Cholesterol
LDL
HDL
Triglycerides
BMI
Weight
Question 4
Row Headers
% of participants
Definition
Diabetes (DM)
Cardiometabolic syndrome (CMS)
Dyslipidemia
Hypertension (HTN)
Chronic Kidney Disease (CKD)
Myocardial infarction (MI, AMI)
Coronary revascularizatino (CABG, PCI, PTCA)
Congestive heart failure (CHF)
Stroke (CVA)
Transient ischemic attack (TIA)
Carotid revascularization
Peripheral vascular disease (PVD)
Supraventricular arrhythmia (SVT (or AFib))
Ventricular tachyarrhythmia
Question 5
Question 6
Question 7


Question 8

Outcome Name Suggestions

Outcome Title Note
bp_SBP
bp_DBP
bp_MAP
lipid_HDL
lipid_LDL
lipid_TC/HDL ratio
lipid_LDL/HDL ratio
lipid_Tg
Placeholder
Death_all cause
Death_Cardiac (all)
Death_Stroke
cardiac_MI
composite_MACE major adverse cardiac/cardiovascular/cerebrovasc events
arrhythmia_Sudden Cardiac Death
cardiac_Unstable Angina
cv_Revascularization define
cardiac_MI or UA
cerebro_Stroke
cerebro_Stroke or TIA
arrhythmia_device insertion
bp_HTN
death_CAD (coronary)
arrhythmia_AFib
cardiac_CHF
arrhythmia_ventricular Clarify whether VT, VF, or both
death_CVD (incl. stroke)
cardiac_revascularization
arrhythmia_composite
cv_CVD (total)
cardiac_Stable Angina
cardiac_MI or CAD death


Outcome Details

Question 1
... Definition
... Definition
... Definition
... Definition
... Definition
... Definition
... Definition
... Definition
... Definition
... Definition
... Definition
... Definition
... Definition
... Definition
... Definition
... Definition
... Definition

Question 2



...
Question 3
Row Headers
Subgroups (A vs. B)
Measure
Relative ES
CI or SE
P_inter
Adjusted?
Note
Subgp Comp 1
Subgp Comp 2
Subgp Comp 3
Subgp Comp 4
Subgp Comp 5
Subgp Comp 6
Subgp Comp 7
Subgp Comp 8
Subgp Comp 9
Subgp Comp 10
Subgp Comp 11
Subgp Comp 12
Question 4

Adverse Events

Arm or Total Title Description Events (n) At Risk (N) Follow-up time
ALA
All n-3 PUFAs (ALA+DHA+EPA)
DHA
"Fish oil" (DHA+EPA)
DHA
EPA
Placebo
Low n-3 diet
No intervention
Placeholder
Fish
Fish + Fish oil

Quality Dimension Fields

Quality Dimension Value Notes
Was the allocation sequence (RANDOMIZATION METHOD) adequately generated?
Was ALLOCATION adequately concealed (prior to assignment)?
Were PARTICIPANTS adequately BLINDED?
Were OUTCOME ASSESSORS adequately BLINDED?
Incomplete outcome data (ATTRITION BIAS) due to amount, nature or handling of incomplete outcome data
Is there evidence of SELECTIVE OUTCOME REPORTING bias (Yes/No)?
INTENTION-TO-TREAT analysis? (Yes/No)
Group SIMILARITY AT BASELINE (**GENERAL**)
Was there incomplete COMPLIANCE with interventions across groups?
Group SIMILARITY AT BASELINE (**OMEGA-3**)
Additional Bias: Bias due to problems not covered elsewhere in the table.
If outcome assessor blinding risk of bias is different for different outcomes (eg, lipids vs. MI), choose HIGH risk of bias and describe in Notes
If attrition risk of bias is different for different outcomes (eg, lipids vs. MI) or different time points (eg, 1 year vs. 5 years), choose HIGH risk of bias and describe in Notes

Overall Rating of Study:
Quality Guideline Used in Assessment: